While More Neurologists Are Using Gilenya Compared to Just Two Months Ago, a Number of Prescribing Obstacles Are Impeding

EXTON, Penn.--(BUSINESS WIRE)-- BioTrends Research Group, LLC finds that, while surveyed neurologists are almost unanimous in reporting that the unique mode of administration of Novartis’s Gilenya is its greatest advantage, they indicate that initial trial and adoption has been hampered by patient resistance, monitoring frustrations, managed care issues, and continued concerns related to potential safety issues. Although the percent of neurologists who have begun to prescribe Gilenya jumped significantly since November 2010, Gilenya’s current share and average patient volume remain relatively low reflecting narrow adoption within individual practices.

The recently released second wave of the LaunchTrends®: Gilenya report series finds that both current Gilenya prescribers and non-prescribers perceive Gilenya as a DMA to be used for switches, although the groups differ with regards to the point at which they would first consider Gilenya for a patient. Although shares of all DMAs—Biogen Idec’s Avonex and Tysabri, Bayer’s Betaseron, Teva’s Copaxone and Pfizer’s Rebif—are expected to be impacted by Gilenya to some degree, neurologists are split on which one of two specific DMAs Gilenya is most likely to replace in their practices. The projected share trends for Gilenya remain favorable as current prescribers anticipate increased use and one-half of current non-prescribers expect to begin trial of Gilenya within the next six months.

LaunchTrends®: Gilenya is a three wave syndicated report series designed to track the uptake of Novartis’s Gilenya at one month, three months and six months following its commercial availability. In the current wave of research, which measures Gilenya’s market impact at one month post launch, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of 20 of the respondents in January 2011. BioTrends will continue to track the uptake of Gilenya in the final wave of this report series, which will be published in May 2011, and in the ongoing TreatmentTrends®: Multiple Sclerosis report series, which is published quarterly.

About LaunchTrends

LaunchTrends assesses trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.



CONTACT:

BioTrends Research Group, LLC
Sharon Funk, 404-223-2963
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.